ArticleMolecular neurobiology2026
P2X7 Receptor Inhibition Mitigates Microglial Activation, Neuroinflammation, and Secondary Thalamic Damage After Ischemic Stroke.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- P2X7 Signaling in Neuroinflammation: Glial Crosstalk, Redox Integration, and Therapeutic Targeting.Journal of molecular neuroscience : MN · 2026Review
- Targeting microglial C1q alleviates blood-brain barrier disruption in the thalamus after cortical infarction.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Secondary damage in remote brain regions following ischemic stroke significantly worsens patient outcomes, yet its underlying mechanisms remain poorly understood. Microglial activation is a central pathological feature of secondary damage, with the P2X7 receptor (P2X7R) emerging as a key regulator of neuroinflammatory processes. In this study, we employed a distal middle cerebral artery occlusion (dMCAO) model in rats to investigate the role of P2X7R in secondary damage in the ventral posterolateral nucleus (VPN) of the ipsilateral thalamus. We observed a spatiotemporal pattern of microglial activation and elevated P2X7R expression in the VPN, coinciding with delayed neuronal loss and gliosis. P2X7R activation drove the NLRP3 inflammasome cascade, leading to the release of interleukin-1β (IL-1β). Inhibition of P2X7R using Brilliant Blue G (BBG) significantly attenuated microglial activation, suppressed the NLRP3/IL-1β axis, and reduced neuronal loss and gliosis in the VPN. Molecular dynamics simulations confirmed BBG's high-affinity binding to P2X7R, while behavioral tests demonstrated improved neurological function. Transcriptome sequencing revealed that P2X7R inhibition by BBG induces profound reprogramming of calcium signaling pathways, suppressing calcium-regulated exocytosis and neuroactive ligand-receptor interactions, while enriching the cAMP pathway. This correlates with BBG's efficacy in attenuating microglial activation, NLRP3/IL-1β axis activation, and neuronal loss. Our findings establish P2X7R as a central driver of neuroinflammation in delayed neurodegeneration after ischemic stroke,and inhibition with P2X7R offers a promising strategy to mitigate secondary damage.
Indexed as
Identifiers
41604093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.